본문으로 가기

학회지 검색

  • Journal of Multiple Sclerosis and Neuroimmunology 12(2):25-34, 2021
  • Obesity in Neurology Practice: Focusing on Recent Advances in Central Acting Anti-Obesity Agents
  • Jang Won Son, MD, PhD
  • Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea
Obesity is a chronic, complex, and heterogeneous disease that is affected by genetic, developmental, biological, and environmental factors. Recent evidence has shown a strong correlation between obesity and neurodegenerative disorders and neurodevelopmental disorders. Metabolic changes due to obesity are associated with damage to the central nervous system, which can cause neuronal death by apoptosis or cell necrosis, as well as alter the synaptic plasticity of neurons. Thus, it is necessary to treat obese neurology patients with an integrated and comprehensive strategy. Currently, three centrally acting anti-obesity drugs (naltrexone extended release [ER]/bupropion ER, phentermine/topiramate, and liraglutide) can promote weight loss by suppressing appetite with prolonged (>12 weeks) use. Pharmacotherapy for obesity should be performed according to an appropriate evaluation of clinical evidence and should be tailored to each patient in consideration of the characteristics of each drug and comorbidities related to obesity. In this review, I discuss the neuroendocrine aspects of obesity and the mechanism of action and efficacy of these available long-term anti-obesity drugs. Journal of Multiple Sclerosis and Neuroimmunology 12(2):25-34, 2021
  • keyword : Obesity; Naltrexone/bupropion extended-release; Phentermine/topiramate extended-release; Liraglutide